Oramed Pharmaceuticals (ORMP) EBITDA Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly EBITDA Margin came in at 225.0% in Q1 2025, up 60.0% on a QoQ basis from 562.46% in Q2 2023.

Oramed Pharmaceuticals (ORMP) EBITDA Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 8 years of EBITDA Margin data on file, last reported at 225.0% in Q1 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 225.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 754.4% (changed N/A YoY) and the FY2025 annual result came in at 754.4%, changed N/A from the prior year.
EBITDA Margin climbed to 225.0% in Q1 2025, from 562.46% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 225.0% in Q1 2025 to a low of 1693.92% in Q2 2022.
A 4-year average of 1051.65% and a median of 1048.44% in 2021 frame the typical range for EBITDA Margin.
The widest YoY moves for EBITDA Margin: up 113145 bps in 2023, down 90751 bps in 2023.
Tracing ORMP's EBITDA Margin over 4 years: stood at 896.15% in 2021, then slumped by 52 bps to 1363.5% in 2022, then soared by 59 bps to 562.46% in 2023, then soared by 60 bps to 225.0% in 2025.
The last three EBITDA Margin figures came in at 225.0% (Q1 2025), 562.46% (Q2 2023), and 781.98% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.25 Bn	131.40 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn	30.15%
3	Argenx Se	65.43 Bn	60.25 Bn	1.37 Bn	32.54%
4	Moderna	58.26 Bn	53.13 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.61 Bn	28.31 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.03 Bn	9.63 Bn	668.28 Mn	-35.57%
8	Insmed	27.49 Bn	26.33 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	19.75%
10	Oramed Pharmaceuticals	199.09 Mn	199.09 Mn	-	-

Download Data